Hypertension affects millions of Americans and has adverse long-term consequences increasing morbidity and mortality. Resistant hypertension (RH) continues to be difficult to treat with medications alone which may be associated with significant side effects. Alternate therapies have been evaluated for treating RH and renal denervation has been investigated extensively. We review the data from renal denervation trials and other novel technologies which are not FDA approved to date.
Keywords: Anti-hypertensive agents; Denervation; Hypertension; Resistant hypertension; Sympathectomy.
Copyright © 2020 Elsevier Inc. All rights reserved.